Cannaray has appointed an ex-JP Morgan executive ahead of a planned public listing.
The firm, which has medical cannabis and CBD interests, has announced E. Stanton McLean will take up the role of executive advisor.
Cannaray are heading for the public markets ‘in the next 12 months’ – but a spokesperson was tight-lipped about further details.
The company could potentially look to join a slew of a cannabis companies turning to the London Stock Exchange or head for alternative market Aquis.
Stanton worked in the bank’s leveraged finance division and spent 25 years at the corporate giant before leaving his current position as managing director this week to join Artemis Growth Partners, an investment platform dedicated to global cannabis.
He has previously served as a non-executive board member for Cannaray.
CEO Scott Maguire said: “We are pleased to welcome Stanton to the team at Cannaray.
“Stanton is a leader who brings a wealth of unique experiences, partnerships and relationships in the global capital markets that will benefit our continued strategic growth and visions, particularly as we look to list Cannaray on the public markets in the next 12 months.
“Cannaray strives to bring the best and brightest to the company along with outstanding characters to build a European-leading cannabis company and Stanton brings these characteristics and then some.”
Stanton said the industry is at ‘pioneer stage’ and that Cannaray could become ‘Europe’s leading cannabis company’.
He added: “As consumers become more educated with regards tot he health benefits of cannabis wellness products, it was clear to me that this was an ideal time to embark on a new challenge with enormous potential. I couldn’t be more excited.”
